ZA989230B - Prostaglandin agonists. - Google Patents

Prostaglandin agonists.

Info

Publication number: ZA989230B
Authority: ZA; South Africa
Prior art keywords: prostaglandin agonists; prostaglandin; agonists
Prior art date: 1997-10-10

Application number

ZA9809230A

Other languages

English (en)

Inventor

Kimberley O'keefe Cameron

Bruce Allen Lefker

Robert Louis Rosati

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-10-10

Filing date

1998-10-09

Publication date

2000-04-10

1998-10-09 Application filed by Pfizer filed Critical Pfizer

2000-04-10 Publication of ZA989230B publication Critical patent/ZA989230B/xx

Links

239000000556 agonist Substances 0.000 title 1
150000003180 prostaglandins Chemical class 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/70—Sulfur atoms
- C07D213/71—Sulfur atoms to which a second hetero atom is attached
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
- C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
- C07C311/46—Y being a hydrogen or a carbon atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/84—Sulfur atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Ophthalmology & Optometry (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pyridine Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
Heterocyclic Compounds Containing Sulfur Atoms (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Furan Compounds (AREA)
Thiazole And Isothizaole Compounds (AREA)
Pyrrole Compounds (AREA)
Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)

ZA9809230A 1997-10-10 1998-10-09 Prostaglandin agonists. ZA989230B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US6172797P	1997-10-10	1997-10-10

Publications (1)

Publication Number	Publication Date
ZA989230B true ZA989230B (en)	2000-04-10

Family

ID=22037728

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA9809230A ZA989230B (en)	1997-10-10	1998-10-09	Prostaglandin agonists.

Country Status (44)

Country	Link
US (2)	US6498172B1 (fr)
EP (1)	EP1021410B1 (fr)
JP (3)	JP3664651B2 (fr)
KR (1)	KR100369697B1 (fr)
CN (2)	CN1211367C (fr)
AP (1)	AP1156A (fr)
AR (1)	AR015954A1 (fr)
AT (1)	ATE349428T1 (fr)
AU (1)	AU731509B2 (fr)
BG (1)	BG65238B1 (fr)
BR (1)	BR9813028A (fr)
CA (1)	CA2305548C (fr)
DE (1)	DE69836752T2 (fr)
DK (1)	DK1021410T3 (fr)
DZ (1)	DZ2621A1 (fr)
EA (1)	EA003396B1 (fr)
ES (1)	ES2277390T3 (fr)
GT (2)	GT199800158AA (fr)
HN (1)	HN1998000157A (fr)
HR (1)	HRP20000201B1 (fr)
HU (1)	HUP0100101A3 (fr)
ID (1)	ID24836A (fr)
IL (2)	IL134851A0 (fr)
IS (1)	IS5405A (fr)
MA (1)	MA26551A1 (fr)
MY (1)	MY129189A (fr)
NO (1)	NO316733B1 (fr)
NZ (1)	NZ503165A (fr)
OA (1)	OA11346A (fr)
PA (1)	PA8461301A1 (fr)
PE (1)	PE121199A1 (fr)
PL (1)	PL340014A1 (fr)
PT (1)	PT1021410E (fr)
RS (1)	RS50012B (fr)
SA (2)	SA98190804B1 (fr)
SI (1)	SI1021410T1 (fr)
SK (1)	SK286136B6 (fr)
TN (1)	TNSN98182A1 (fr)
TR (1)	TR200000927T2 (fr)
TW (1)	TW570913B (fr)
UA (1)	UA67754C2 (fr)
UY (1)	UY25204A1 (fr)
WO (1)	WO1999019300A1 (fr)
ZA (1)	ZA989230B (fr)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
UA67754C2 (uk)	1997-10-10	2004-07-15	Пфайзер, Інк.	Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти)
EP1000619A3 (fr) *	1998-06-23	2002-07-24	Pfizer Products Inc.	Méthode de traitement du glaucome
JP4834224B2 (ja)	1999-03-05	2011-12-14	デュークユニバーシティ	Ｃ１６不飽和ｆｐ−選択的プロスタグランジン類縁体
US6894175B1 (en)	1999-08-04	2005-05-17	The Procter & Gamble Company	2-Decarboxy-2-phosphinico prostaglandin derivatives and methods for their preparation and use
TWI262185B (en) *	1999-10-01	2006-09-21	Eisai Co Ltd	Carboxylic acid derivatives having anti-hyperglycemia and anti-hyperlipemia action, and pharmaceutical composition containing the derivatives
IL141120A0 (en)	2000-01-31	2002-02-10	Pfizer Prod Inc	Use of prostaglandin (pge2) receptor 4 (epa) selective agonists for the treatment of acute and chronic renal failure
US20010056060A1 (en) *	2000-02-07	2001-12-27	Cameron Kimberly O.	Treatment of osteoporsis with EP2/EP4 receptor selective agonists
US20020037914A1 (en)	2000-03-31	2002-03-28	Delong Mitchell Anthony	Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
US20020172693A1 (en)	2000-03-31	2002-11-21	Delong Michell Anthony	Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US20020013294A1 (en)	2000-03-31	2002-01-31	Delong Mitchell Anthony	Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
WO2003043576A2 (fr) *	2001-11-20	2003-05-30	Depuy Products, Inc.	Compositions osteogeniques et chondrogeniques fluentes
GEP20063951B (en) *	2001-11-30	2006-10-25	Pfizer	Controlled release polymeric compositions of bone growth promoting compounds
AU2002348948A1 (en) *	2001-11-30	2003-06-10	Pfizer Products Inc.	Pharmaceutical compositions and methods for administering EP2 receptors selective agonists
PY0300568A (es) *	2002-01-31	2004-10-01	Pfizer Prod Inc	Metabolitos del acido(3-{[4-terc-butilbencil)-(piridin-3-sulfonil)amino]metil}fenoxi)acetico
WO2003087061A1 (fr) *	2002-04-12	2003-10-23	Pfizer Japan Inc.	Composes de pyrazole en tant qu'agents anti-inflammatoires et analgesiques
MXPA04011690A (es)	2002-05-24	2005-03-31	Pharmacia Corp	Moduladores de receptor x de higado de sulfona.
MXPA04011691A (es)	2002-05-24	2005-09-12	Pharmacia Corp	Moduladores del receptor x anilino hepaticos.
JP2006021998A (ja) *	2002-07-18	2006-01-26	Ono Pharmaceut Co Ltd	Ｅｐ２アゴニストを有効成分とする月経困難症治療剤
ES2584606T3 (es)	2002-10-10	2016-09-28	Ono Pharmaceutical Co., Ltd.	Microesferas que comprenden ONO-1301
GB0302094D0 (en)	2003-01-29	2003-02-26	Pharmagene Lab Ltd	EP4 receptor antagonists
NZ541828A (en) *	2003-03-04	2008-06-30	Pfizer Prod Inc	Use of EP2 selective receptor agonists in medical treatment
EP2422814A1 (fr)	2003-07-25	2012-02-29	Ono Pharmaceutical Co., Ltd.	Remède pour maladies associées aux cartilages
WO2005027931A1 (fr) *	2003-09-19	2005-03-31	Pfizer Products Inc.	Compositions pharmaceutiques et methodes de traitement consistant en des associations d'un derive de la 2-alkylidene-19-nor-vitamine d et d'un agoniste selectif de ep2 ou ep4
GB0324269D0 (en)	2003-10-16	2003-11-19	Pharmagene Lab Ltd	EP4 receptor antagonists
US20050203086A1 (en) *	2004-03-04	2005-09-15	Pfizer Inc.	Methods of treatment using an EP2 selective receptor agonist
JP2008503561A (ja) *	2004-06-21	2008-02-07	ファルマシア・アンド・アップジョン・カンパニー・エルエルシー	骨芽細胞機能を刺激するためのｐｙｋ２阻害薬
EP1841749A1 (fr)	2004-09-02	2007-10-10	Metabasis Therapeutics, Inc.	Derives d'inhibiteurs de thiazole et de thiadiazoles de tyrosine phosphatases
JP4893999B2 (ja)	2004-10-22	2012-03-07	小野薬品工業株式会社	吸入用医薬組成物
US8604055B2 (en)	2004-12-31	2013-12-10	Dr. Reddy's Laboratories Ltd.	Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
WO2006073973A2 (fr)	2004-12-31	2006-07-13	Reddy Us Therapeutics, Inc.	Nouveaux dérivés de benzylamine en tant qu'inhibiteurs de cetp
AU2006253356B2 (en)	2005-06-03	2011-12-01	Ono Pharmaceutical Co., Ltd.	Agent for regeneration and/or protection of nerves
US7915316B2 (en)	2005-08-22	2011-03-29	Allergan, Inc	Sulfonamides
US7696235B2 (en) *	2005-08-29	2010-04-13	Allergan, Inc.	EP2 receptor agonists for treating glaucoma
EP2059507B1 (fr) *	2006-07-28	2013-03-20	Pfizer Products Inc.	Agoniste de ep2
UA94953C2 (en) *	2006-07-28	2011-06-25	Пфайзер Продактс Инк.	Ep2 agonists
WO2008058766A1 (fr)	2006-11-16	2008-05-22	Bayer Schering Pharma Aktiengesellschaft	Agonistes ep2 et ep4 en tant qu'agents destinés au traitement d'une infection virale de l'influenza a
US9394520B2 (en) *	2006-12-08	2016-07-19	University Of Rochester	Expansion of hematopoietic stem cells
KR101558193B1 (ko) *	2007-08-21	2015-10-12	세노믹스, 인코포레이티드	인간 ｔ2ｒ 쓴맛 수용체 및 이의 용도
EP2185516A2 (fr) *	2007-08-29	2010-05-19	Pfizer Products Incorporated	Formes polymorphes d'agonistes de prostaglandine et procédés de fabrication de celles-ci
US20110046385A1 (en) *	2007-08-29	2011-02-24	Pfizer Products Inc.	Polymorphs Of Prostaglandin Agonists And Methods For Making The Same
WO2009027803A2 (fr) *	2007-08-29	2009-03-05	Pfizer Products Inc.	Formes polymorphes d'acide libre d'acide acétique 3-(((4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino)-méthyl)- phénoxy)
HUE042839T2 (hu)	2008-03-12	2019-07-29	Ube Industries	Piridilaminoecetsav vegyületek
EP2149551A1 (fr)	2008-07-30	2010-02-03	Bayer Schering Pharma AG	Dérivés de N-(indol-3-ylalkyl)-(hétéro)arylamide en tant que modulateurs du récepteur EP2
EP2149554A1 (fr)	2008-07-30	2010-02-03	Bayer Schering Pharma Aktiengesellschaft	Indolylamides en tant que modulateurs du récepteur EP2
EP2149552A1 (fr)	2008-07-30	2010-02-03	Bayer Schering Pharma AG	Dérivés de benzamide 5,6 substitués en tant que modulateurs du récepteur EP2
HRP20160104T1 (hr)	2009-03-30	2016-03-25	Ube Industries	Farmaceutski pripravak za liječenje ili prevenciju glaukoma
WO2010116270A1 (fr)	2009-04-10	2010-10-14	Pfizer Inc.	Agonistes de ep2/4
EP2520570A4 (fr)	2009-12-25	2013-07-17	Ube Industries	Composé d'aminopyridine
EP3056198A2 (fr)	2010-09-16	2016-08-17	MSP Co., Ltd	Utilisation de composés permettant d'induire la différenciation de cellules souches mésenchymateuses en chondrocytes
US9199967B2 (en)	2011-08-18	2015-12-01	Dr. Reddy's Laboratories Ltd.	Substituted heterocyclic amine compounds as cholestryl ester-transfer protein (CETP) inhibitors
MX352074B (es)	2011-09-27	2017-11-08	Dr Reddys Laboratories Ltd	Derivados de 5-bencilaminometil-6-aminopirazolo [3,4-b] piridina como inhibidores de proteina de transferencia de ester de colesterilo (cetp) utiles para el tratamiento de aterosclerosis.
US8772541B2 (en) *	2011-12-15	2014-07-08	University of Pittsburgh—of the Commonwealth System of Higher Education	Cannabinoid receptor 2 (CB2) inverse agonists and therapeutic potential for multiple myeloma and osteoporosis bone diseases
ES2733998T3 (es)	2012-10-29	2019-12-03	Cardio Incorporated	Agente terapéutico específico de enfermedad pulmonar
CA2902624C (fr)	2013-02-28	2021-05-18	Takeda Pharmaceutical Company Limited	Procede de production d'un compose de chlorure de sulfonyle
JPWO2014157672A1 (ja)	2013-03-28	2017-02-16	宇部興産株式会社	置換ビアリール化合物
US9968716B2 (en)	2013-10-15	2018-05-15	Ono Pharmaceutical Co., Ltd.	Drug-eluting stent graft
JP2017206444A (ja) *	2014-09-26	2017-11-24	宇部興産株式会社	置換フェニル化合物
CN114591227A (zh) *	2021-12-28	2022-06-07	上海冬洋生物科技有限公司	一种ep2受体选择性的前列腺素e2激动剂的制备方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR897566A (fr)	1942-08-28	1945-03-26	Bopp & Reuther Gmbh	Machine à rotors
US3442890A (en)	1965-06-15	1969-05-06	Mead Johnson & Co	Substituted 3-benzazocin-16-ones
US3528961A (en)	1966-08-16	1970-09-15	Allied Chem	Monoazo dyes from e-caprolactam
US3780095A (en)	1970-04-08	1973-12-18	Byk Gulden Lomberg Chem Fab	Acylated anilino-carboxylic acids and their salts
US3987091A (en)	1973-04-12	1976-10-19	Merck & Co., Inc.	11,12-secoprostaglandins
US4033996A (en)	1973-04-25	1977-07-05	Merck & Co., Inc.	8-Aza-9-oxo(and dioxo)-thia-11,12-secoprostaglandins
JPS5019756A (fr)	1973-06-25	1975-03-01
SE7414770L (fr)	1973-12-13	1975-06-16	Merck & Co Inc
DK366475A (da)	1974-08-30	1976-03-01	Merck & Co Inc	Fremgangsmade til fremstilling af aryloxy- eller arylthioholdige secoprostaglandiner
US3991106A (en)	1974-09-13	1976-11-09	Merck & Co., Inc.	16-Ethers of 8-aza-9-dioxothia-11,12-seco-prostaglandins
US4055596A (en)	1974-09-13	1977-10-25	Merck & Co., Inc.	11,12-Seco-prostaglandins
US4175203A (en)	1976-12-17	1979-11-20	Merck & Co., Inc.	Interphenylene 11,12-secoprostaglandins
US4112236A (en)	1977-04-04	1978-09-05	Merck & Co., Inc.	Interphenylene 8-aza-9-dioxothia-11,12-secoprostaglandins
US4097601A (en)	1977-08-26	1978-06-27	Pfizer Inc.	Bone deposition by 2-descarboxy-2-(tetrazol-5-yl)-11-dexosy-16-aryl prostaglandins
US4243678A (en)	1977-12-30	1981-01-06	Byk Gulden Lomberg Chemische Fabrik Gmbh	Acylhydrocarbylaminoalkanoic acids, compositions and uses
DE3000377A1 (de)	1980-01-07	1981-07-09	Boehringer Mannheim Gmbh, 6800 Mannheim	Neue sulfonamide, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel
DE3042482A1 (de)	1980-11-11	1982-06-24	A. Nattermann & Cie GmbH, 5000 Köln	N-benzoyl- (omega) -anilinoalkancarbonsaeuren, -salze und -ester, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate
EP0068968B1 (fr)	1981-06-16	1985-09-18	Choay S.A.	Nouveaux médicaments contenant à titre de substance active des composés du type arylbenzènesulfonamide et leurs procédés de préparation
DK373383A (da)	1982-08-20	1984-02-21	Midit	Fremgangsmaade til fremstilling af omega-aminosyrederivater
DE3719046A1 (de)	1987-06-06	1988-12-15	Basf Ag	Verwendung von salzen von sulfonamidcarbonsaeuren als korrosionsinhibitoren in waessrigen systemen
US5084466A (en) *	1989-01-31	1992-01-28	Hoffmann-La Roche Inc.	Novel carboxamide pyridine compounds which have useful pharmaceutical utility
US5081152A (en)	1989-07-05	1992-01-14	Kotobuki Seiyaku Co., Ltd.	Azulene derivatives as thromboxane a2 and prostaglandin endoperoxide receptor antagonist
JPH0467105A (ja) *	1990-07-09	1992-03-03	Nippon Telegr & Teleph Corp <Ntt>	偏波保持光ファイバ
GB9110722D0 (en) *	1991-05-17	1991-07-10	Fujisawa Pharmaceutical Co	Amine derivatives
GB9116732D0 (en) *	1991-08-02	1991-09-18	Fujisawa Pharmaceutical Co	Indole derivatives
CA2113787A1 (fr) *	1993-01-29	1994-07-30	Nobuyuki Hamanaka	Sulfonamides carbocycliques
HN1996000101A (es) *	1996-02-28	1997-06-26	Inc Pfizer	Terapia combinada para la osteoporosis
DE19648793A1 (de)	1996-11-26	1998-05-28	Basf Ag	Neue Benzamide und deren Anwendung
UA59384C2 (uk) *	1996-12-20	2003-09-15	Пфайзер, Інк.	Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі
AUPO440696A0 (en) *	1996-12-30	1997-01-23	Fujisawa Pharmaceutical Co., Ltd.	New use
UA67754C2 (uk)	1997-10-10	2004-07-15	Пфайзер, Інк.	Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти)
AU2002348948A1 (en) *	2001-11-30	2003-06-10	Pfizer Products Inc.	Pharmaceutical compositions and methods for administering EP2 receptors selective agonists
PY0300568A (es) *	2002-01-31	2004-10-01	Pfizer Prod Inc	Metabolitos del acido(3-{[4-terc-butilbencil)-(piridin-3-sulfonil)amino]metil}fenoxi)acetico

1998
- 1998-05-10 UA UA2000042002A patent/UA67754C2/uk unknown
- 1998-10-05 EP EP98944169A patent/EP1021410B1/fr not_active Expired - Lifetime
- 1998-10-05 RS YUP-184/00A patent/RS50012B/sr unknown
- 1998-10-05 BR BR9813028-5A patent/BR9813028A/pt not_active Application Discontinuation
- 1998-10-05 TR TR2000/00927T patent/TR200000927T2/xx unknown
- 1998-10-05 HR HR980440A patent/HRP20000201B1/xx not_active IP Right Cessation
- 1998-10-05 SI SI9830873T patent/SI1021410T1/sl unknown
- 1998-10-05 CN CNB988100266A patent/CN1211367C/zh not_active Expired - Fee Related
- 1998-10-05 KR KR10-2000-7003851A patent/KR100369697B1/ko not_active Expired - Fee Related
- 1998-10-05 NZ NZ503165A patent/NZ503165A/en unknown
- 1998-10-05 ID IDW20000647A patent/ID24836A/id unknown
- 1998-10-05 PL PL98340014A patent/PL340014A1/xx unknown
- 1998-10-05 PT PT98944169T patent/PT1021410E/pt unknown
- 1998-10-05 AT AT98944169T patent/ATE349428T1/de not_active IP Right Cessation
- 1998-10-05 CN CNA2004100385354A patent/CN1566096A/zh active Pending
- 1998-10-05 JP JP2000515873A patent/JP3664651B2/ja not_active Expired - Fee Related
- 1998-10-05 IL IL13485198A patent/IL134851A0/xx active IP Right Grant
- 1998-10-05 AU AU91815/98A patent/AU731509B2/en not_active Ceased
- 1998-10-05 DE DE69836752T patent/DE69836752T2/de not_active Expired - Lifetime
- 1998-10-05 US US09/367,970 patent/US6498172B1/en not_active Expired - Fee Related
- 1998-10-05 DK DK98944169T patent/DK1021410T3/da active
- 1998-10-05 WO PCT/IB1998/001540 patent/WO1999019300A1/fr not_active Ceased
- 1998-10-05 EA EA200000298A patent/EA003396B1/ru not_active IP Right Cessation
- 1998-10-05 ES ES98944169T patent/ES2277390T3/es not_active Expired - Lifetime
- 1998-10-05 CA CA002305548A patent/CA2305548C/fr not_active Expired - Fee Related
- 1998-10-05 SK SK475-2000A patent/SK286136B6/sk not_active IP Right Cessation
- 1998-10-05 HU HU0100101A patent/HUP0100101A3/hu unknown
- 1998-10-06 HN HN1998000157A patent/HN1998000157A/es unknown
- 1998-10-06 PA PA19988461301A patent/PA8461301A1/es unknown
- 1998-10-07 TW TW087116614A patent/TW570913B/zh not_active IP Right Cessation
- 1998-10-07 MY MYPI98004598A patent/MY129189A/en unknown
- 1998-10-08 AP APAP/P/1998/001356A patent/AP1156A/en active
- 1998-10-08 UY UY25204A patent/UY25204A1/es not_active IP Right Cessation
- 1998-10-09 ZA ZA9809230A patent/ZA989230B/xx unknown
- 1998-10-09 PE PE1998000956A patent/PE121199A1/es not_active Application Discontinuation
- 1998-10-09 GT GT199800158AK patent/GT199800158AA/es unknown
- 1998-10-09 TN TNTNSN98182A patent/TNSN98182A1/fr unknown
- 1998-10-09 MA MA25288A patent/MA26551A1/fr unknown
- 1998-10-09 GT GT199800158A patent/GT199800158A/es unknown
- 1998-10-09 AR ARP980105053A patent/AR015954A1/es active IP Right Grant
- 1998-10-10 DZ DZ980231A patent/DZ2621A1/fr active
- 1998-11-23 SA SA98190804A patent/SA98190804B1/ar unknown
- 1998-11-23 SA SA6260449A patent/SA06260449B1/ar unknown
2000
- 2000-03-02 IL IL134851A patent/IL134851A/en not_active IP Right Cessation
- 2000-03-14 IS IS5405A patent/IS5405A/is unknown
- 2000-03-31 OA OA1200000097A patent/OA11346A/en unknown
- 2000-04-05 NO NO20001754A patent/NO316733B1/no not_active IP Right Cessation
- 2000-04-07 BG BG104315A patent/BG65238B1/bg unknown
2002
- 2002-09-25 US US10/256,198 patent/US7442702B2/en not_active Expired - Fee Related
2003
- 2003-06-12 JP JP2003167713A patent/JP4031736B2/ja not_active Expired - Fee Related
2007
- 2007-04-25 JP JP2007115825A patent/JP4796006B2/ja not_active Expired - Fee Related

Also Published As

Publication number	Publication date
DE69836752T2 (de)	2007-10-11
SI1021410T1 (sl)	2007-06-30
KR20010031035A (ko)	2001-04-16
HUP0100101A3 (en)	2001-12-28
SA98190804B1 (ar)	2006-07-30
NO316733B1 (no)	2004-04-14
PL340014A1 (en)	2001-01-15
AR015954A1 (es)	2001-05-30
AU9181598A (en)	1999-05-03
SK4752000A3 (en)	2001-05-10
GT199800158A (es)	2000-04-01
TW570913B (en)	2004-01-11
BG104315A (en)	2000-12-29
OA11346A (en)	2003-12-11
AP1156A (en)	2003-06-30
PE121199A1 (es)	1999-12-02
YU18400A (sh)	2003-08-29
ID24836A (id)	2000-08-24
ATE349428T1 (de)	2007-01-15
MY129189A (en)	2007-03-30
MA26551A1 (fr)	2004-12-20
PT1021410E (pt)	2007-02-28
HN1998000157A (es)	1999-06-02
EP1021410A1 (fr)	2000-07-26
ES2277390T3 (es)	2007-07-01
HK1031884A1 (en)	2001-06-29
HRP20000201B1 (en)	2003-06-30
KR100369697B1 (ko)	2003-02-05
UY25204A1 (es)	2000-12-29
CA2305548A1 (fr)	1999-04-22
RS50012B (sr)	2008-09-29
DK1021410T3 (da)	2007-04-02
AU731509B2 (en)	2001-03-29
GT199800158AA (es)	2000-04-01
EA200000298A1 (ru)	2000-10-30
US6498172B1 (en)	2002-12-24
CN1566096A (zh)	2005-01-19
JP2001519414A (ja)	2001-10-23
IL134851A0 (en)	2001-05-20
HUP0100101A2 (hu)	2001-06-28
HRP20000201A2 (en)	2000-06-30
PA8461301A1 (es)	2000-05-24
WO1999019300A1 (fr)	1999-04-22
UA67754C2 (uk)	2004-07-15
SA98190804A (ar)	2005-12-03
TR200000927T2 (tr)	2000-11-21
IS5405A (is)	2000-03-14
JP4796006B2 (ja)	2011-10-19
US7442702B2 (en)	2008-10-28
JP2007246532A (ja)	2007-09-27
BG65238B1 (bg)	2007-09-28
EA003396B1 (ru)	2003-04-24
SA06260449B1 (ar)	2007-08-07
EP1021410B1 (fr)	2006-12-27
JP3664651B2 (ja)	2005-06-29
CA2305548C (fr)	2008-12-02
BR9813028A (pt)	2000-08-15
JP4031736B2 (ja)	2008-01-09
NZ503165A (en)	2001-07-27
JP2004155759A (ja)	2004-06-03
AP9801356A0 (en)	1998-12-31
IL134851A (en)	2007-06-17
DZ2621A1 (fr)	2003-03-08
DE69836752D1 (de)	2007-02-08
NO20001754L (no)	2000-06-07
CN1211367C (zh)	2005-07-20
NO20001754D0 (no)	2000-04-05
TNSN98182A1 (fr)	2005-03-15
CN1275123A (zh)	2000-11-29
SK286136B6 (sk)	2008-04-07
US20030078261A1 (en)	2003-04-24

Publication	Publication Date	Title
ZA989230B (en)	2000-04-10	Prostaglandin agonists.
ZA989767B (en)	2000-04-28	Novel compounds.
ZA98970B (en)	1999-08-06	N-hydroxy-ß-sulfonyl propionamide derivatives.
ZA200005136B (en)	2001-03-02	Dihydropyrimides.
AU7349298A (en)	1999-01-04	Prostaglandin agonists
ZA981017B (en)	1999-08-10	2-amino-6-(2-substituted-4-phenoxy)-substituted-pyridines.
ZA991272B (en)	1999-08-18	Novel thiobenzamides.
ZA982918B (en)	1999-10-06	Luminaire.
ZA9711567B (en)	1998-06-24	Compounds.
DE59804842D1 (en)	2002-08-22	Aliphatische, emissionsarme, sinterfähige thermoplastische polyurethanformmassen
ZA981926B (en)	1999-09-06	Detergent--package combination.
ZA987058B (en)	2000-02-07	Substituted 4-benzoylpyrazoles.
ZA987055B (en)	2000-02-07	Substituted 4-benzoylpyrazoles.
ZA975861B (en)	1998-01-30	Bromotiacumicin compounds.
ZA9811758B (en)	2000-06-22	Novel compounds.
ZA9811503B (en)	2000-06-15	Novel compounds.
ZA982436B (en)	1999-09-23	Thiazolimine derivatives.
ZA987029B (en)	2000-02-07	Synchronizer.
ZA983705B (en)	1999-11-01	Pregnan-3-ol-20-ones.
ZA974052B (en)	1998-01-14	New benzothiazolinones.
ZA987B (en)	1999-07-02	Substituted 4-benzoylpyrazoles.
ZA98868B (en)	1999-08-03	Novel compounds.
ZA979404B (en)	1998-06-01	Aspirinate compounds.
ZA988206B (en)	2000-03-09	Piperidinylmethyloxazolidinone derivative.
ZA974056B (en)	1998-01-14	New thiazolopyridines.